trial

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

NCTId NCT00585390
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 0 (actual)
Sponsored by University of Cincinnati
Primary completion 2009-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-01
Primary completion
2009-11
Eligibility
ALL · 8 Years · 25 Years

Interventions & indications

Drugs
Omega-3 fatty acidsEPA fish oil concentrate; DHA fish oil concentrate

Sponsors

University of CincinnatiLead Sponsor

Investigators

1
Neil Richtand, MDPrincipal Investigator

Sites

1 total
Cincinnati, United States

Linked catalysts

1
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia — primary completion2009-11

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2,PHASE3
Primary Completion Date
2009-11
Status
COMPLETED
relationships
The graph out of here
drug
Omega-3 fatty acids
drug
EPA fish oil concentrate; DHA fish oil concentrate
drug
lead_sponsor
University of Cincinnati
company
indication
Schizophrenia
indication
Schizophrenia
indication
Fatty Acid Deficiency
indication
investigator
Neil Richtand, MD
person